Professional Documents
Culture Documents
U2 Pregnancy in Women With Congenital Heart
U2 Pregnancy in Women With Congenital Heart
Clinical update
Congenital heart defects are the most common birth defects. Major advances in open-heart surgery have led to rapidly evolving cohorts of adult
survivors and the majority of affected women now survive to childbearing age. The risk of cardiovascular complications during pregnancy and
peripartum depends on the type of the underlying defect, the extent and severity of residual haemodynamic lesions and comorbidities. Careful
individualized, multi-disciplinary pre-pregnancy risk assessment and counselling, including assessment of risks in the offspring and estimation on
long-term outcomes of the underlying heart defect, will enable informed decision making. Depending on the estimated risks, a careful follow-up
plan during pregnancy as well as a detailed plan for delivery and postpartum care can reduce the risks and should be made by the multi-
* Corresponding author. Tel: +41 44 255 3883, Fax: +41 44 255 8701, Email: matthias.greutmann@usz.ch
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2015. For permissions please email: journals.permissions@oup.com.
Page 2 of 11 M. Greutmann and P.G. Pieper
The extent of these haemodynamic changes in healthy women is il- or failure to adequately increase heart rate or cardiac output
lustrated in Figure 2. (chronotropic incompetence, inadequate adaptation of pacemaker
Depending on the type and complexity of the congenital cardiac programming, valve stenosis, rigid conduits, or baffles) during preg-
defect and the severity of residual haemodynamic lesions, these nor- nancy and peripartum may further impair these adaptive mechan-
mal adaptive responses of the cardiovascular system to the in- isms and precipitate decompensation.
creased demands of pregnancy, labour, and puerpurium can be The occurrence of obstetric complications, such as hypertensive
distorted in numerous ways.16 The occurrence of tachy-arrhythmias disorders of pregnancy, pre-eclampsia, or multiple pregnancies in-
crease the haemodynamic load of pregnancy and thus increase
the risk of maladaptation to haemodynamic needs and subsequently
increase the risk of cardiovascular complications in vulnerable pa-
tients.8,17 – 19 The increased risk of multiple pregnancies may be of
particular importance in women seeking assisted fertilization and
underscores the need for optimal multi-disciplinary pre-pregnancy
communication, counselling, and planning. Assisted reproductive
technologies carry in it risks that may endanger the pregnant woman
with cardiovascular disease, such as fluid retention and enhance-
ment of hypercoagulability.20
Figure 2 Haemodynamic changes during pregnancy, peripartum, and postpartum. (A) Pregnancy (weeks of gestation). Modified from Robson
et al.12 (B) Peripartum. Modified from: Adams et al.13 BC, between contractions; Peak, at the peak of contraction; Stage 3, at the time of uterine
contraction. (C) Postportum. Modified from Robson et al.14,15 24 h pp, 24 h postpartum; 2w pp, 2 weeks postpartum. *For cohorts in (B) and (C),
relative changes from baseline were compared with the baseline values of the cohort from (A).
Pregnancy in women with congenital heart disease Page 3 of 11
Over the last few decades, there has been rapidly growing Box 1 Factors associated with high maternal
evidence on pregnancy risks for a variety of CHD. One source of risk8,18,22,25,27
evidence stems from lesion-specific studies. Most of these studies
are retrospective studies and often comprise relatively small num- Congenital heart defects/residual hemodynamic lesions with very
high maternal risk
bers of pregnancies at risk and a wide variety of residual haemo-
(High risk of maternal mortality, consensus that pregnancy should be
dynamic lesions within specific groups of CHD. With the advent discouraged)
of large multi-centre registries, such as the ROPAC registry, more † Severe symptomatic aortic valve stenosis
detailed data on lesion-specific outcomes will help better individual † Severe left atrio-ventricular valve stenosis
risk stratification in the future. A meta-analysis summarizing the re- † Pulmonary arterial hypertension
† Systemic ventricular ejection fraction ,30%
sults of lesion-specific studies, published in 2007 by the ZAHARA
† Poor functional class (NYHA III and IV)
investigators, provides a useful estimation of the spectrum of risks † Marfan syndrome with ascending aortic diameter .45 mm
for a given CHD.25 All these studies are however flawed by the im- † Bicuspid aortic valve with ascending aortic diameter .50 mm
portant biases of such small retrospective series and therefore must † Unrepaired severe coarctation
be used carefully in individual decision making. Another source of Congenital heart defects/residual haemodynamic lesions with
high maternal risk 8,18,22,25,27
evidence stems from studies on larger numbers of women with
(High risk of morbidity or increased risk of maternal mortality,
various forms of heart diseases and thus could define risk factors consensus that very careful pre-pregnancy assessment and counselling
for adverse outcomes based on patient history and residual haemo- is required)
dynamic lesions and define risk scores.8,9,16 Based on these sources † Mechanical heart valve prosthesis
of evidence and on collective clinical experience, expert panels have † Systemic right ventricle (transposition of the great arteries after
atrial switch operations or congenitally corrected transposition
defined risk-categories based on the underlying CHD, specific
of the great arteries)
haemodynamic residue as well as past medical history (see Figure 3 † Fontan palliation for univentricular hearts
and corresponding Box 1). This so-called modified WHO classifica- † Unrepaired or palliated cyanotic heart conditions
tion of maternal pregnancy risk has prospectively been validated † Marfan syndrome with ascending aortic diameter ,40 mm
as the most reliable method of risk assessment.26 Though this is a † Severe systemic atrio-ventricular valve regurgitation
† Asymptomatic left ventricular outflow tract stenosis with peak
helpful tool for risk estimation, it should be emphasized that risk
Figure 3 Multi-disciplinary, multi-step risk assessment, counselling, and management planning (Refs 6,8,18,22,25,27 – 34).
blood flow may be the result of maternal impaired haemodynam- The recurrence risk of isolated CHDs in the offspring is on aver-
ics, explaining partly the increased foetal complication rate in age 3–5%.39 There is however substantial variability in recurrence
women with CHD.38 risk, depending on familial occurrence and type of defect.40,41 The
Pregnancy in women with congenital heart disease Page 5 of 11
recurrence risk is particularly high in left ventricular outflow tract safe and effective contraception and when she desires to embark on
obstruction, including the hypoplastic left heart syndrome.42 Some a pregnancy, to visit her cardiologist for an up-to-date assessment of
CHDs are associated with syndromes such as the 22q11 microdele- pregnancy risk (including echocardiography and exercise testing)
tion syndrome (cono-truncal defects), Noonan syndrome (pulmon- and construction of a pregnancy management plan before discon-
ary stenosis, atrial septal defects), and the Holt-Oram-syndrome tinuing her contraceptive.
(atrial and ventricular septal defects). In these syndromes, inherit- For women, who wish to become pregnant it is important to
ance is autosomal dominant and recurrence risk is 50%. Genetic clearly define management during pregnancy and to provide obstet-
testing using cord blood samples can be discussed with the affected ric assessment to ascertain up-to-date vaccination and initiation of
couple. In all patients with CHDs, including male patients, recur- appropriate prophylactic measures, such as folic acid supplementa-
rence risk should be discussed and counselling by a geneticist should tion as well as recommendations for smoking cessation and abstin-
be offered. Counselling by a geneticist may be particularly important ence from alcohol.
in patients asking for pre-implantation testing in the context of
assisted fertilization.
Management of pregnancy in
Effect of pregnancy on long-term women with congenital heart
outcomes disease
Only few studies have assessed the impact of pregnancy on long-
term outcomes in women with heart disease. For women with General aspects
subaortic right ventricles in the setting of transposition of the For each pregnancy, a clear follow-up plan must be provided. The con-
great arteries after atrial switch operations, there is a small but tent of this plan is dependant on the estimated maternal and foetal risk.
definitive—and unpredictable—risk of irreversible deterioration of While high-risk pregnancies (see Figure 3, Box 1) must be managed by a
systolic dysfunction of the subaortic systemic right ventricle.28,43,44 dedicated, experienced multi-disciplinary team at a tertiary care cen-
A case – control study in women with dilated cardiomyopathy and tre, women at low risk for cardiovascular and foetal complications can
systemic ventricular dysfunction suggests an increased short-term often be managed at regional centres. Good collaboration between
Figure 4 Multi-disciplinary team. CHD, congenital heart disease; EP, electrophysiology; ICU, intensive care unit; PHT, pulmonary hypertension.
Additional teams and services may need to be involved (i.e. social service) as per individual needs of the pregnant woman. In some services, ma-
Box 2 Risk of neonatal events8,18,35 If the assessment reveals a very high-risk condition (see Figure 3,
Box 1), termination of pregnancy should be discussed, preferably
Maternal pre-pregnancy functional class .II or cyanosis early in pregnancy. However, termination of pregnancy carries risks
Maternal left heart obstruction and for women with high-risk lesions this should be performed in a
Smoking during pregnancy
tertiary centre.
Multiple gestation
Use of oral anti-coagulants during pregnancy
Mechanical heart valve prosthesis Need for intervention or cardiac surgery
during pregnancy
Although percutaneous interventions are generally possible during
Submaximal exercise testing to evaluate exercise capacity, heart
pregnancy, the decision to perform such an intervention requires
rate, and blood pressure response to exercise and exercise-induced
careful interdisciplinary assessment with weighing risks and benefits.
arrhythmias can be safely performed during pregnancy.22 Given the
Procedures should be performed by experienced teams at tertiary
high chance of spontaneous miscarriage before 12 weeks, it may how-
care centres only, with an aim to keep the radiation dose to the foe-
ever be prudent to avoid exercise testing in the first trimester, if pos-
tus as minimal as possible by shortening radiation time, using bra-
sible, as any temporal relationship between miscarriage and exercise
chial artery access and shielding of the uterus. If possible, the
testing may be misconstrued as causal rather than pure chance. When
intervention should be performed in the second trimester after
an exercise test is performed, the aim is to achieve 80% of the pre-
completion of organogenesis but before the uterus has become
dicted heart rate. As chronotropic incompetence is common in adults
very large. The timing of interventions remains debateable, how-
with CHD, cardio-pulmonary exercise testing with measuring
ever. Open-heart surgery on cardio-pulmonary bypass carries a
gas-exchange, aiming for a respiratory exchange ratio of 1.0 may be
high risk of foetal loss. If cardiac surgery can be delayed until the
an alternative to standard bicycle or treadmill exercise testing.
28th week of gestation, prior delivery after lung maturity induction
The use of cardiac magnetic resonance imaging is regarded safe,
should be considered.22
particularly after the first trimester, but the use of gadolinium-
contrast should be avoided. This may be particularly indicated for
imaging of the entire aorta in women with Marfan syndrome or Occurrence and management of heart
other aortic diseases. Methods using ionizing radiation (radiography, failure in pregnancy and peripartum
computed tomography, or scintigraphy) are generally avoided, A recent multi-centre study has shown two peaks for the occur-
unless they provide critical information that cannot be obtained rence of heart failure in women with heart disease.50 One peak
with other methods.22 was towards the end of the second trimester of pregnancy, when
Pregnancy in women with congenital heart disease Page 7 of 11
the cardiovascular demands reach their plateau and the second peak with corticosteroids may lead to fluid retention and worsening
was peri- and early postpartum. It is however important to empha- of heart failure. After restoration of haemodynamic stability post-
size that the manifestation of heart failure may differ between differ- partum, afterload reduction with angiotensin-converting-enzyme
ent types of CHD as well as between individuals. inhibitors should be started.
Towards later stages of pregnancy diagnosis of heart failure In women with cardiac pacemakers and implanted cardiac defi-
may be difficult as its signs and symptoms (shortness of breath brillators it is important to document the current programming of
on exertion, peripheral oedema, and sinus tachycardia) may be the device (i.e. the heart rate, when anti-tachycardia pacing or defib-
difficult to distinguish from normal findings in late pregnancy. rillation will be administered). In the case of any uncertainties, it is
Clinical judgment of fluid status is important and must be supple- advisable to consult the patient’s cardiologist and/or electrophysi-
mented by regular laboratory and echocardiographic assess- ologist in order to discuss the need for modifications of pacemaker
ments. A chest X-ray is relatively harmless for the foetus and or defibrillator programming.
can be performed when required. Serial measurements of natri-
uretic peptides (Pro-BNP or BNP) may help in risk stratifica- Women with mechanical heart valves
tion. 30,33 Normal levels of natriuretic peptides at 20 weeks of Women with mechanical heart valves are at high risk of thrombo-
pregnancy seem to provide a good negative predictive value embolic events.52 – 54 Several strategies of anti-coagulation have
regarding the occurrence of cardiovascular complications. Al- been reported.53,55,56Anti-coagulation with vitamin K antagonists
though elevated or rising levels of natriuretic peptides do not ne- throughout pregnancy is safest for the mother and provides the low-
cessarily predict cardiovascular complications, it may be prudent est risk for valve thrombosis.22,53 Offspring of women requiring low
to follow these women closely. doses of vitamin K antagonists (,5 mg Warfarin or ,3 mg phen-
If overt heart failure occurs during pregnancy, patients should be procoumon) to maintain therapeutic international normalized ratios
admitted to a tertiary care centre. Precipitating factors, such as have a low risk of embryopathy and foetal loss compared with those
(intermittent) arrhythmia, should be actively sought and excluded. requiring higher doses.52,57 – 61 Continuation of the vitamin K antag-
Bed rest, supplemental oxygen, and careful fluid balance with daily onist throughout pregnancy should be considered in these wo-
weight measurements should be initiated. Inotropes may be needed men.22 Heparins are associated with more valve thrombosis but
to improve heart failure and careful administration of diuretics
Table 1 Obstetric drugs, their cardiovascular side effects and precautions in women with congenital heart disease
Arrhythmias increase the risk of thromboembolic complications stability a rate- or rhythm control strategy must be chosen, although
and are an important trigger for the occurrence of heart failure. rhythm control is often preferred over rate control in pregnant wo-
Women with new-onset palpitations or sudden worsening of short- men with CHD and new-onset arrhythmias. Regarding anti-
ness of breath thus require prompt assessment by the multi- arrhythmic drug treatment, b-blockers are first choice for most ar-
disciplinary team. Most women with sustained or severely symp- rhythmias. A detailed list regarding recommendations for drug use
tomatic arrhythmias during pregnancy need to be admitted. De- during pregnancy and lactation can be found within the ESC guide-
pending on the underlying cardiac condition and haemodynamic lines.22 Careful assessment for the need for anti-coagulation is
mandatory.
Figure 5 Residual intra-cardiac shunt with risk of paradoxical embolism. (A) Echocardiographic four-chamber view after injection of agitated
saline contrast in a patient with sinus venosus defect, demonstrating large, spontaneous right-to-left shunting. (B) Intravenous line with air filter
(bubble trap) to prevent accidental systemic air embolism.
8. Siu SC, Sermer M, Colman JM, Alvarez AN, Mercier LA, Morton BC, Kells CM, contraception in heart disease and pulmonary arterial hypertension. J Fam Plann
Bergin ML, Kiess MC, Marcotte F, Taylor DA, Gordon EP, Spears JC, Tam JW, Reprod Health Care 2006;32:75– 81.
Amankwah KS, Smallhorn JF, Farine D, Sorensen S. Prospective multicenter study 28. Bowater SE, Selman TJ, Hudsmith LE, Clift PF, Thompson PJ, Thorne SA. Long-term
of pregnancy outcomes in women with heart disease. Circulation 2001;104: outcome following pregnancy in women with a systemic right ventricle: is the de-
515 –521. terioration due to pregnancy or a consequence of time? Congenit Heart Dis 2013;8:
9. Roos-Hesselink JW, Ruys TP, Stein JI, Thilen U, Webb GD, Niwa K, Kaemmerer H, 302 –307.
Baumgartner H, Budts W, Maggioni AP, Tavazzi L, Taha N, Johnson MR, Hall R, RO- 29. Grewal J, Siu SC, Ross HJ, Mason J, Balint OH, Sermer M, Colman JM,
PAC Investigators. Outcome of pregnancy in patients with structural or ischaemic Silversides CK. Pregnancy outcomes in women with dilated cardiomyopathy.
heart disease: results of a registry of the European Society of Cardiology. Eur Heart J J Am Coll Cardiol 2009;55:45–52.
2013;34:657 –665. 30. Kampman MA, Balci A, van Veldhuisen DJ, van Dijk AP, Roos-Hesselink JW,
10. Gelson E, Gatzoulis MA, Steer P, Johnson MR. Heart disease – why is maternal Sollie-Szarynska KM, Ludwig-Ruitenberg M, van Melle JP, Mulder BJ, Pieper PG, ZA-
mortality increasing? BJOG 2009;116:609 –611. HARA II Investigators. N-terminal pro-B-type natriuretic peptide predicts cardio-
11. Bush N, Nelson-Piercy C, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M, Ukoss. vascular complications in pregnant women with congenital heart disease. Eur Heart
Myocardial infarction in pregnancy and postpartum in the UK. Eur J Prev Cardiol J 2014;35:708 –715.
2013;20:12 –20. 31. Lui GK, Silversides CK, Khairy P, Fernandes SM, Valente AM, Nickolaus MJ,
12. Robson SC, Hunter S, Boys RJ, Dunlop W. Serial study of factors influencing Earing MG, Aboulhosn JA, Rosenbaum MS, Cook S, Kay JD, Jin Z, Gersony DR,
changes in cardiac output during human pregnancy. Am J Physiol 1989;256(4 Pt Alliance for Adult Research in Congenital C. Heart rate response during exercise
2):H1060 –5. and pregnancy outcome in women with congenital heart disease. Circulation 2011;
13. Adams JQ, Alexander AM Jr. Alterations in cardiovascular physiology during labor. 123:242–248.
Obstet Gynecol 1958;12:542 –549. 32. Silversides CK, Sermer M, Siu SC. Choosing the best contraceptive method for the
14. Robson SC, Dunlop W, Boys RJ, Hunter S. Cardiac output during labour. Br Med J adult with congenital heart disease. Curr Cardiol Rep 2009;11:298 –305.
(Clin Res Ed) 1987;295:1169 –1172. 33. Tanous D, Siu SC, Mason J, Greutmann M, Wald RM, Parker JD, Sermer M,
15. Robson SC, Dunlop W, Hunter S. Haemodynamic changes during the early puer- Colman JM, Silversides CK. B-type natriuretic peptide in pregnant women with
perium. Br Med J (Clin Res Ed) 1987;294:1065. heart disease. J Am Coll Cardiol 2010;56:1247 –1253.
16. Cornette J, Ruys TP, Rossi A, Rizopoulos D, Takkenberg JJ, Karamermer Y, Opic P, 34. Tobler D, Greutmann M, Colman JM, Greutmann-Yantiri M, Librach LS,
Van den Bosch AE, Geleijnse ML, Duvekot JJ, Steegers EA, Roos-Hesselink JW. Kovacs AH. End-of-life in adults with congenital heart disease: a call for early com-
Hemodynamic adaptation to pregnancy in women with structural heart disease. munication. Int J Cardiol 2012;155:383 –387.
Int J Cardiol 2013;168:825 – 831. 35. Siu SC, Colman JM, Sorensen S, Smallhorn JF, Farine D, Amankwah KS, Spears JC,
17. Robson SC, Hunter S, Boys RJ, Dunlop W. Hemodynamic changes during twin Sermer M. Adverse neonatal and cardiac outcomes are more common in pregnant
pregnancy. A Doppler and M-mode echocardiographic study. Am J Obstet Gynecol women with cardiac disease. Circulation 2002;105:2179 –2184.
1989;161:1273 –1278. 36. Harrild DM, Berul CI, Cecchin F, Geva T, Gauvreau K, Pigula F, Walsh EP. Pulmon-
18. Drenthen W, Boersma E, Balci A, Moons P, Roos-Hesselink JW, Mulder BJ,
48. Greutmann M, Tobler D, Colman JM, Greutmann-Yantiri M, Librach SL, 58. Vitale N, De Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-
Kovacs AH. Facilitators of and barriers to advance care planning in adult congenital dependent fetal complications of warfarin in pregnant women with mechanical
heart disease. Congenit Heart Dis 2013;8:281 – 288. heart valves. J Am Coll Cardiol 1999;33:1637 –1641.
49. Reid GJ, Webb GD, Barzel M, McCrindle BW, Irvine MJ, Siu SC. Estimates of life 59. Salazar E, Izaguirre R, Verdejo J, Mutchinick O. Failure of adjusted doses of
expectancy by adolescents and young adults with congenital heart disease. J Am subcutaneous heparin to prevent thromboembolic phenomena in pregnant pa-
Coll Cardiol 2006;48:349 –355. tients with mechanical cardiac valve prostheses. J Am Coll Cardiol 1996;27:
50. Ruys TP, Roos-Hesselink JW, Hall R, Subirana-Domenech MT, Grando-Ting J, 1698 – 1703.
Estensen M, Crepaz R, Fesslova V, Gurvitz M, De Backer J, Johnson MR, 60. Cotrufo M, De Feo M, De Santo LS, Romano G, Della Corte A, Renzulli A, Gallo C.
Pieper PG. Heart failure in pregnant women with cardiac disease: data from the Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol
ROPAC. Heart 2014;100:231–238. 2002;99:35 –40.
51. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet 2006;368:687–693. 61. Iturbe-Alessio I, Fonseca MC, Mutchinik O, Santos MA, Zajarias A, Salazar E. Risks
52. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med
heart valves: a systematic review of the literature. Arch Intern Med 2000;160:191–196.
1986;315:1390 – 1393.
53. Hirsh J, Cade JF, Gallus AS. Fetal effects of coumadin administered during preg-
62. Elkayam U, Bitar F. Valvular heart disease and pregnancy: part II: prosthetic valves.
nancy. Blood 1970;36:623 –627.
J Am Coll Cardiol 2005;46:403 –410.
54. Pieper PG, Balci A, Van Dijk AP. Pregnancy in women with prosthetic heart valves.
63. Bouchardy J, Therrien J, Pilote L, Ionescu-Ittu R, Martucci G, Bottega N, Marelli AJ.
Neth Heart J 2008;16:406–411.
Atrial arrhythmias in adults with congenital heart disease. Circulation 2009;120:
55. McLintock C, McCowan LM, North RA. Maternal complications and pregnancy
1679 –1686.
outcome in women with mechanical prosthetic heart valves treated with enoxa-
parin. BJOG 2009;116:1585 –1592. 64. Kaemmerer H, Fratz S, Bauer U, Oechslin E, Brodherr-Heberlein S, Zrenner B,
56. Yinon Y, Siu SC, Warshafsky C, Maxwell C, McLeod A, Colman JM, Sermer M, Turina J, Jenni R, Lange PE, Hess J. Emergency hospital admissions and three-year
Silversides CK. Use of low molecular weight heparin in pregnant women with survival of adults with and without cardiovascular surgery for congenital cardiac
mechanical heart valves. Am J Cardiol 2009;104:1259 –1263. disease. J Thorac Cardiovasc Surg 2003;126:1048 –1052.
57. Hassouna A, Allam H. Limited dose warfarin throughout pregnancy in patients with 65. Ouyang DW, Khairy P, Fernandes SM, Landzberg MJ, Economy KE. Obstetric out-
mechanical heart valve prosthesis: a meta-analysis. Interact Cardiovasc Thorac Surg comes in pregnant women with congenital heart disease. Int J Cardiol 2010;144:
2014;18:797 –806. 195 –199.